CA2972757C - Immunotherapie anti-tumorale combinee - Google Patents

Immunotherapie anti-tumorale combinee

Info

Publication number
CA2972757C
CA2972757C CA2972757A CA2972757A CA2972757C CA 2972757 C CA2972757 C CA 2972757C CA 2972757 A CA2972757 A CA 2972757A CA 2972757 A CA2972757 A CA 2972757A CA 2972757 C CA2972757 C CA 2972757C
Authority
CA
Canada
Prior art keywords
seq
antibody
certain embodiments
cpi
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2972757A
Other languages
English (en)
Other versions
CA2972757A1 (fr
Inventor
Arthur M. Krieg
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Priority claimed from PCT/US2015/067269 external-priority patent/WO2016109310A1/fr
Publication of CA2972757A1 publication Critical patent/CA2972757A1/fr
Application granted granted Critical
Publication of CA2972757C publication Critical patent/CA2972757C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne des procédés de traitement du cancer au moyen d'une administration locale de certains oligonucléotides CpG (CpG ODN) et d'une administration systémique d'un inhibiteur de point de contrôle, tel qu'un anticorps anti-PD-1, un anticorps anti-PD-L1 et/ou un anticorps anti-CTLA-4. Dans des modes de réalisation préférés, les CpG ODN sont sélectionnés sur base de leur propension à induire des quantités élevées d'interféron alpha (IFN-a) et de l'activation des lymphocytes T par rapport à l'interleukine-10 (IL-10) et l'activation des lymphocytes B. Dans certains modes de réalisation, les procédés comprennent en outre le prétraitement par une radiothérapie, pour potentialiser l'immunothérapie combinée.
CA2972757A 2014-12-31 2015-12-22 Immunotherapie anti-tumorale combinee Active CA2972757C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462098568P 2014-12-31 2014-12-31
US62/098,568 2014-12-31
US201562106526P 2015-01-22 2015-01-22
US62/106,526 2015-01-22
US201562118165P 2015-02-19 2015-02-19
US62/118,165 2015-02-19
PCT/US2015/067269 WO2016109310A1 (fr) 2014-12-31 2015-12-22 Immunothérapie anti-tumorale combinée

Publications (2)

Publication Number Publication Date
CA2972757A1 CA2972757A1 (fr) 2016-07-07
CA2972757C true CA2972757C (fr) 2025-09-09

Family

ID=

Similar Documents

Publication Publication Date Title
US20260069624A1 (en) Combination tumor immunotherapy
US20250255898A1 (en) Compositions and methods for tumor immunotherapy
US11326170B2 (en) Immunomodulatory polynucleotides and uses thereof
EP3209778B1 (fr) Association médicamenteuse
US20120003179A1 (en) Anti-ctla-4 and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
US20210315991A1 (en) Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer
CA2972757C (fr) Immunotherapie anti-tumorale combinee
HK1246319B (en) Combination tumor immunotherapy
US12460208B2 (en) Immunomodulatory polynucleotides and uses thereof